Persones / Equip Humà

Marçal Pastor-Anglada

Buscador de publicacions

Publicacions

  • Fernández-Calotti P, Casulleras-Gras O, Antolin M, Guarner F and Pastor-Anglada M.

    Galectin-4 interacts with the drug transporter human concentrative nucleoside transporter 3 to regulate its function

    FASEB JOURNAL . 30(2): 544-554. Nº de cites: 9

    [doi:10.1096/fj.15-272773]

  • Kretschmar C, Oyarzún C, Villablanca C, Jaramillo C, Alarcón S, Perez G, Díaz-Encarnación MM, Pastor-Anglada M, Garrido W, Quezada C and San Martín R.

    Reduced Adenosine Uptake and Its Contribution to Signaling that Mediates Profibrotic Activation in Renal Tubular Epithelial Cells: Implication in Diabetic Nephropathy

    PLoS One . 11(1): . Nº de cites: 26

    [doi:10.1371/journal.pone.0147430]

  • Veyhl-Wichmann M, Friedrich A, Vernaleken A, Singh S, Kipp H, Gorboulev V, Keller T, Chintalapati C, Pipkorn R, Pastor-Anglada M, Groll J and Koepsell H.

    Phosphorylation of RS1 (RSC1A1) Steers Inhibition of Different Exocytotic Pathways for Glucose Transporter SGLT1 and Nucleoside Transporter CNT1, and an RS1-Derived Peptide Inhibits Glucose Absorption

    MOLECULAR PHARMACOLOGY . 89(1): 118-132. Nº de cites: 22

    [doi:10.1124/mol.115.101162]

  • Arimany-Nardi C, Minuesa G, Keller T, Erkizia I, Koepsell H, Martinez-Picado J and Pastor-Anglada M.

    Role of Human Organic Cation Transporter 1 (hOCT1) Polymorphisms in Lamivudine (3TC) Uptake and Drug-Drug Interactions.

    FRONTIERS IN PHARMACOLOGY . 7: 175-175. Nº de cites: 15

    [doi:10.3389/fphar.2016.00175]

  • Arimany-Nardi C, Koepsell H and Pastor-Anglada M.

    Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions

    PHARMACOGENOMICS JOURNAL . 15(6): 473-487. Nº de cites: 27

    [doi:10.1038/tpj.2015.78]

  • Arimany-Nardi C, Montraveta A, Lee-Vergés E, Puente XS, Koepsell H, Campo E, Colomer D and Pastor-Anglada M.

    Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells

    PHARMACOGENOMICS JOURNAL . 15(4): 363-371. Nº de cites: 15

    [doi:10.1038/tpj.2014.77]

  • Claudio-Montero A, Pinilla-Macua I, Fernández-Calotti P, Sancho-Mateo C, Lostao MP, Colomer D, Grandas A and Pastor-Anglada M.

    Fluorescent Nucleoside Derivatives as a Tool for the Detection of Concentrative Nucleoside Transporter Activity Using Confocal Microscopy and Flow Cytometry

    MOLECULAR PHARMACEUTICS . 12(6): 2158-2166. Nº de cites: 6

    [doi:10.1021/acs.molpharmaceut.5b00142]

  • Minami K, Shinsato Y, Yamamoto M, Takahashi H, Zhang S, Nishizawa Y, Tabata S, Ikeda R, Kawahara K, Tsujikawa K, Chijiiwa K, Yamada K, Akiyama S, Perez-Torras S, Pastor-Anglada M, Furukawa T and Yasuo T.

    Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors

    JOURNAL OF PHARMACOLOGICAL SCIENCES . 127(3): 319-325. Nº de cites: 39

    [doi:10.1016/j.jphs.2015.01.006]

  • Pastor-Anglada M and Perez-Torras S.

    Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets.

    FRONTIERS IN PHARMACOLOGY . 6: 13-13. Nº de cites: 81

    [doi:10.3389/fphar.2015.00013]

  • Godoy V, Banales JM, Medina JF and Pastor-Anglada M.

    Functional crosstalk between the adenosine transporter CNT3 and purinergic receptors in the biliary epithelia.

    JOURNAL OF HEPATOLOGY . 61(6): 1337-1343. Nº de cites: 9

    [doi:10.1016/j.jhep.2014.06.036]